Willingness of Chinese Injection Drug Users to Participate in HIV Vaccine Trials

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2008 Jan 15

PMID 18191881

Citations 13

Authors

Lu Yin

Yuanzhi Zhang

Han-Zhu Qian

Baoling Rui

Lijiang Zhang

Junling Zhu

Yongsheng Guan

Yunxia Wang

Qingchun Li

Yuhua Ruan

Yiming Shao

Affiliations

Soon will be listed here.

Abstract

Background: Chinese injection drug users (IDUs) may be a proper candidate population for HIV vaccine trials.

Objective: To evaluate willingness to participate (WTP) in HIV vaccine trials among Chinese IDUs.

Methods: Questionnaire interviews were completed among 401 IDUs in Urumqi City in northwestern China in 2005.

Results: Overall 74.3% of participants said that they would be definitely willing to participate in HIV vaccine trials, 17.7% were probably willing, 6.2% were probably not willing, and remaining 1.8% were definitely not willing to join. Multivariate logistic regression analysis demonstrated that WTP was positively associated with having ever had sex with a drug use partner (adjusted odds ratio [AOR]: 1.8; 95% confidence interval [CI]: 1.04, 3.2), sharing needle and syringe with a new drug use partner in the past 3 months (AOR: 3.8; 95% CI: 1.2, 11.7), perceived family support for participation (AOR: 7.4; 95% CI: 4.3, 12.7), and perceived vaccine protection against HIV infection (AOR: 16.1; 95% CI: 3.7, 70.8), and was negatively associated with perceived risk of social stigma and isolation for participation (AOR: 0.3; 95% CI: 0.2, 0.5).

Conclusions: The stated WTP in hypothetical HIV vaccine trials was high among Chinese IDUs. Further studies are needed to evaluate actual enrollment into the trials.

Citing Articles

Willingness to Participate in Hypothetical HIV Vaccine Trial and Associated Factors among People Who Inject Drugs in Dar es Salaam, Tanzania.

Iseselo M, Tarimo E, Sandstrom E, Kulane A Biomed Res Int. 2020; 2020:8507981.

PMID: 32714988 PMC: 7354640. DOI: 10.1155/2020/8507981.

The willingness to participate in biomedical research involving human beings in low- and middle-income countries: a systematic review.

Browne J, Rees C, van Delden J, Agyepong I, Grobbee D, Edwin A Trop Med Int Health. 2018; 24(3):264-279.

PMID: 30565381 PMC: 6850431. DOI: 10.1111/tmi.13195.

Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults-Experience from Kenya.

Nyasani D, Mutua G, Sajabi R, Nganga J, Gachie J, Maina A PLoS One. 2018; 13(11):e0206656.

PMID: 30388145 PMC: 6214541. DOI: 10.1371/journal.pone.0206656.

Motivations to participate in a Phase I/II HIV vaccine trial: A descriptive study from Dar es Salaam, Tanzania.

Tarimo E, Bakari M, Kakoko D, Kohi T, Mhalu F, Sandstrom E BMC Public Health. 2016; 16:182.

PMID: 26911203 PMC: 4765221. DOI: 10.1186/s12889-016-2875-6.

Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.

Dong Y, Shen X, Guo R, Liu B, Zhu L, Wang J PLoS One. 2014; 9(11):e111321.

PMID: 25372044 PMC: 4221013. DOI: 10.1371/journal.pone.0111321.

References

Piyasirisilp S, McCutchan F, Carr J, Sanders-Buell E, Liu W, Chen J . A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000; 74(23):11286-95. PMC: 113233. DOI: 10.1128/jvi.74.23.11286-11295.2000. View

Dhalla S, Woods R, Strathdee S, Patrick D, Hogg R . HIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries. AIDS Care. 2007; 19(9):1118-27. DOI: 10.1080/09540120701352258. View

Halpern S, Metzger D, Berlin J, Ubel P . Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001; 27(3):281-8. DOI: 10.1097/00126334-200107010-00011. View

Esparza J, Osmanov S, Toure C, Chang M, Nixon S . Past, present and future of HIV vaccine trials in developing countries. Vaccine. 2002; 20(15):1897-8. DOI: 10.1016/s0264-410x(02)00062-2. View

MacQueen K, Vanichseni S, Kitayaporn D, Lin L, Buavirat A, Naiwatanakul T . Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999; 21(3):243-51. DOI: 10.1097/00126334-199907010-00010. View

Ding Y, Detels R, Zhao Z, Zhu Y, Zhu G, Zhang B . HIV infection and sexually transmitted diseases in female commercial sex workers in China. J Acquir Immune Defic Syndr. 2005; 38(3):314-9. View

Ruan Y, Qin G, Liu S, Qian H, Zhang L, Zhou F . HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr. 2005; 39(4):459-63. DOI: 10.1097/01.qai.0000152398.47025.0f. View

Golub E, Purvis L, Sapun M, Safaeian M, Beyrer C, Vlahov D . Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users. AIDS Behav. 2005; 9(3):301-9. DOI: 10.1007/s10461-005-9004-3. View

Qian H, Qian Z, Vermund S, Wang N . Risk of HIV/AIDS in China: subpopulations of special importance. Sex Transm Infect. 2005; 81(6):442-7. PMC: 1745065. DOI: 10.1136/sti.2004.014258. View

10.

Chen X, Yin Y, Liang G, Gong X, Li H, Poumerol G . Sexually transmitted infections among female sex workers in Yunnan, China. AIDS Patient Care STDS. 2005; 19(12):853-60. DOI: 10.1089/apc.2005.19.853. View

11.

Li X, Kusagawa S, Xia X, Yang C, Wang Q, Yokota Y . Molecular epidemiology of the heterosexual HIV-1 transmission in Kunming, Yunnan Province of China suggests origin from the local IDU epidemic. AIDS Res Hum Retroviruses. 2006; 21(11):977-80. DOI: 10.1089/aid.2005.21.977. View

12.

Ji G, Detels R, Wu Z, Yin Y . Correlates of HIV infection among former blood/plasma donors in rural China. AIDS. 2006; 20(4):585-91. DOI: 10.1097/01.aids.0000210613.45212.c4. View

13.

Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, Poundstone K . Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. Sex Transm Infect. 2006; 82 Suppl 3:iii87-91. PMC: 2576728. DOI: 10.1136/sti.2006.020404. View

14.

Qian H, Vermund S, Kaslow R, Coffey C, Chamot E, Yang Z . Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS. 2006; 20(10):1429-35. PMC: 2749723. DOI: 10.1097/01.aids.0000233577.33973.fa. View

15.

Woratanarat T . Global HIV cohort studies among injecting drug users and future vaccine trials. J Med Assoc Thai. 2006; 89(7):1064-79. View

16.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F . Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194(12):1661-71. DOI: 10.1086/508748. View

17.

Ruan Y, Cao X, Qian H, Zhang L, Qin G, Jiang Z . Syphilis among female sex workers in southwestern China: potential for HIV transmission. Sex Transm Dis. 2006; 33(12):719-23. DOI: 10.1097/01.olq.0000218881.01437.99. View

18.

Wei L, Chen J, Rodolph M, Beauchamp G, Masse B, Li R . HIV incidence, retention, and changes of high-risk behaviors among rural injection drug users in Guangxi, China. Subst Abus. 2007; 27(4):53-61. DOI: 10.1300/j465v27n04_07. View

19.

Tian L, Ma Z, Ruan Y, Cao X, Huang J, Wang D . [Incidence rates of human immunodeficiency virus and syphilis as well as the rate of retention in a 6-month follow-up study of female sex workers in areas with heavy drug use in Xichang of Sichuan province, China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2007; 27(11):939-42. View

20.

Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Masse B . HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis. 2007; 11(4):318-23. DOI: 10.1016/j.ijid.2006.09.001. View